ROSGQ.US Rosetta Genomics Ltd
- Market cap
- USD 592.00
- P/E
- -
- P/B
- 0.01x
- ROE
- -794.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2017.
Is ROSGQ.US undervalued?
Graham numberThe Graham number of Rosetta Genomics Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Rosetta Genomics Ltd fundamental analysis
No fundamental analysis for Rosetta Genomics Ltd yet.
Rosetta Genomics Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Rosetta Genomics Ltd
Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It also provides UroVysion, a urine-based Fluorescence In S…
Full company profileRosetta Genomics Ltd financial statements
2017 annualized: Fiscal year 2017 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2017, the balance sheet is the latest quarter. Figures change when the annual report is published.
Rosetta Genomics Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 1.51M | 150K | 279K | 103K | 201K | 405K | 1.33M | 8.27M | 9.23M | 3.35M |
| Gross Profit | - | 1.16M | -189K | -349K | -221K | -57.0K | -304K | 17.0K | 2.00M | 1.80M | 1.11M |
| Operating Income | -11.0M | -14.1M | -14.8M | -13.9M | -8.78M | -8.27M | -13.3M | -14.3M | -15.7M | -15.7M | -7.27M |
| EBITDA | -10.9M | -13.8M | -14.5M | -12.5M | -6.92M | -7.99M | -12.9M | -14.2M | -16.5M | -15.3M | - |
| Net Income | -14.7M | -9.46M | -16.5M | -14.8M | -8.83M | -10.5M | -12.9M | -14.5M | -17.3M | -16.2M | -8.73M |
| EPS | -947 | -566 | -877 | -628 | -209 | -28 | -16 | -16 | -14 | -9.31 | -343 |
| Balance Sheet | |||||||||||
| Total Assets | 26.0M | 20.3M | 12.7M | 5.29M | 2.04M | 32.5M | 25.9M | 17.3M | 22.4M | 12.0M | 6.21M |
| Total Liabilities | 2.43M | 4.17M | 5.90M | 5.92M | 2.40M | 1.63M | 2.25M | 2.21M | 2.80M | 7.54M | 5.11M |
| Shareholders' Equity | 23.6M | 16.1M | 6.84M | -1.43M | -356K | 30.9M | 23.6M | 15.1M | 19.6M | 4.42M | 1.10M |
| Cash & Short-term Investments | 22.0M | 15.0M | 9.23M | 3.31M | 735K | 30.8M | 16.8M | 7.93M | 12.4M | 6.16M | 1.33M |
| Total Debt | 263K | 970K | 1.67M | 50.0K | 30.0K | - | - | - | - | 3.80M | 2.49M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -8.07M | -11.9M | -11.8M | -13.7M | -11.3M | -8.64M | -10.6M | -13.6M | -16.9M | -10.4M | -11.4M |
| Capital Expenditure | 714K | 431K | 199K | 425K | 11.0K | 270K | 626K | 247K | 273K | 223K | 28.0K |
| Free Cash Flow | -8.78M | -12.4M | -12.0M | -14.1M | -11.3M | -8.91M | -11.2M | -13.8M | -17.2M | -10.6M | - |
| Ratios | |||||||||||
| ROE | -62.1% | -58.8% | -241.2% | - | - | -33.8% | -54.6% | -96.4% | -88.4% | -367.5% | -794.3% |
| ROA | -56.3% | -46.7% | -129.5% | -278.8% | -432.0% | -32.1% | -49.8% | -84.1% | -77.4% | -135.7% | -140.6% |
| Net Profit Margin | - | -626.3% | -11,003.3% | -5,288.5% | -8,572.8% | -5,202.5% | -3,184.4% | -1,094.6% | -209.8% | -175.8% | -260.7% |
| Debt to Equity | 0.01x | 0.06x | 0.24x | - | - | - | - | - | - | 0.86x | 2.26x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Rosetta Genomics Ltd dividends
Rosetta Genomics Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 1:12 on Mar 17, 2017.
Who owns Rosetta Genomics Ltd
Ownership data of Rosetta Genomics Ltd is not available yet.
Rosetta Genomics Ltd company profile
- Company name
- Rosetta Genomics Ltd
- Ticker
- ROSGQ.US
- ISIN
- IL0011026494
- Exchange
- USA Stocks
- Listed since
- Feb 27, 2007
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 86
- Fiscal year end
- December
- Address
- 10 Plaut Street, Rehovot, Israel, 76706
- Phone
- 972 73 222 0700
- Website
- rosettagenomics.com
About Rosetta Genomics Ltd
Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It also provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay that is intended for use in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer; and ERG/PTEN, which are FISH-based prognostic tests in prostate cancer. In addition, the company offers ALK/ROS1 that are FISH-based predictive tests indicated for patients who are diagnosed with late stage lung cancer; and PCR gene mutation analysis for bladder, lung, colon, and melanoma patients. The company provides its diagnostic solutions for oncologists, urologists, endocrinologists, cytopathologists, and other specialists to facilitate them in serving their patients. It has a license agreement with Max Planck Innovation GmbH for the rights to its proprietary microRNAs for diagnostics and research purposes. The company also has a collaboration agreement with Meir Medical Center to develop a microRNA classifier relating to patients with non-small cell lung cancer considered for treatment with immuno oncology drugs. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.
Rosetta Genomics Ltd management
2- Mr. Douglas SitesExecutive Vice President of Sales & Marketing
- Prof. Zvi Bentwich M.D.Deputy Chairman of the Scientific Advisory Board